<p>Peregrine Capital Management LLC 根据最新提交给美国证券交易委员会（SEC）的 13F 文件显示，在第二季度增持了 Ultragenyx Pharmaceutical Inc.（纳斯达克股票代码：RARE - Free Report）的股份，持股比例增加了 24.7%。该公司在本季度购入了 29,474 股，持有这家生物制药公司的 148,813 股股份。Peregrine Capital Management LLC 在最新提交的 SEC 文件中拥有的 Ultragenyx Pharmaceutical 股份价值 611.6 万美元，占该公司价值的约 0.18%。</p>
<ul>
<li>分析师表示这两家中型生物科技公司有着两倍的潜力</li>
</ul>
<p>其他一些大型投资者也对他们在 RARE 的持仓进行了调整。Headlands Technologies LLC 在第一季度购入了 Ultragenyx Pharmaceutical 的新股份，价值 28,000 美元。UMB Bank n.a.在第二季度增加了对 Ultragenyx Pharmaceutical 的持仓，持股比例增长了 58.1%。UMB Bank n.a.现在拥有 958 股这家生物制药公司的股份，价值 39,000 美元，较上一季度增持了 352 股。GAMMA Investing LLC 在第一季度将其对 Ultragenyx Pharmaceutical 的持仓增加了 622.3%。GAMMA Investing LLC 现在拥有 1,004 股这家生物制药公司的股份，价值 47,000 美元，较上一季度增持了 865 股。Van ECK Associates Corp 在第四季度将其对 Ultragenyx Pharmaceutical 的持仓增加了 34.0%。Van ECK Associates Corp 现在拥有 1,578 股这家生物制药公司的股份，价值 75,000 美元，较上一季度增持了 400 股。最后，International Assets Investment Management LLC 在第四季度将其对 Ultragenyx Pharmaceutical 的持仓增加了 3,182.4%。International Assets Investment Management LLC 现在拥有 1,674 股这家生物制药公司的股份，价值 80,000 美元，较上一季度增持了 1,623 股。该公司的 97.67% 股份由机构投资者和对冲基金持有。</p>
<h2>Ultragenyx Pharmaceutical 股价表现</h2>
<p>Ultragenyx Pharmaceutical 股票周五下跌 0.18 美元，收于 56.78 美元。公司成交 754,442 股，相比平均成交量 805,332 股有所下降。该公司的 50 日移动平均价为 47.29 美元，200 日移动平均价为 45.70 美元。该公司市值为 47.2 亿美元，市盈率为-7.07，β系数为 0.56。Ultragenyx Pharmaceutical Inc.的 52 周最低价为 31.52 美元，52 周最高价为 58.73 美元。</p>
<p>Ultragenyx Pharmaceutical（纳斯达克股票代码：RARE - Get Free Report）最近公布了截至 8 月 1 日星期四的季度财报。该生物制药公司报告本季度每股亏损 1.52 美元，超过了分析师预期的 1.64 美元，增加了 0.12 美元。本季度营收为 1.4703 亿美元，超过分析师预期的 1.232 亿美元。Ultragenyx Pharmaceutical 的净利润率为-121.57%，净资产收益率为-266.02%。公司营收同比增长 35.7%。去年同期，该公司每股亏损 2.25 美元。分析师预计，Ultragenyx Pharmaceutical Inc.今年将实现每股-6.24 美元的盈利。</p>
<h2>分析师评级变动</h2>
<p>一些研究分析师最近发布了关于该公司的报告。Wedbush 将 Ultragenyx Pharmaceutical 的目标股价从 43.00 美元上调至 46.00 美元，并在 8 月 2 日星期五的研究报告中给予该股票 “中性” 评级。Robert W. Baird 将 Ultragenyx Pharmaceutical 的目标股价从 68.00 美元上调至 72.00 美元，并在 5 月 31 日星期五的研究报告中给予该股票 “跑赢市场” 评级。Cantor Fitzgerald 将 Ultragenyx Pharmaceutical 的目标股价从 115.00 美元上调至 116.00 美元，并在 8 月 2 日星期五的研究报告中给予该股票 “增持” 评级。Canaccord Genuity Group 重申了对 Ultragenyx Pharmaceutical 的 “买入” 评级，并设定了 111.00 美元的目标股价。Wells Fargo &amp; Company 将 Ultragenyx Pharmaceutical 的目标股价从 72.00 美元上调至 75.00 美元，并在 8 月 2 日星期五的研究报告中给予该股票 “增持” 评级。两位股票研究分析师给予该股票持有评级，十三位给予买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “中度买入”，平均目标股价为 87.43 美元。</p>
<p><strong>获取我们关于 RARE 的最新报告</strong></p>
<h2>内部交易</h2>
<p>另外，Ultragenyx 制药公司的首席执行官 Emil D. Kakkis 在交易日期为 8 月 6 日星期二出售了 20,000 股 Ultragenyx 制药公司股票。这些股票的平均售价为 50.17 美元，总价值为 1,003,400.00 美元。交易完成后，首席执行官直接持有公司股票 2,243,985 股，价值 112,580,727.45 美元。该销售交易已在提交给证券交易委员会的申报文件中披露，可通过此链接访问。另外，首席执行官 Emil D. Kakkis 还在 8 月 6 日星期二进行的另一笔交易中出售了该公司股票的 20,000 股。这些股票的平均售价为 50.17 美元，交易总额为 1,003,400.00 美元。交易完成后，首席执行官直接持有公司股票 2,243,985 股，价值 112,580,727.45 美元。该交易已在提交给证券交易委员会的申报文件中披露，可通过 SEC 网站访问。此外，董事 Corazon（Corsee）D. Sanders 在 6 月 10 日星期一进行的交易中出售了 1,737 股公司股票。这些股票的平均售价为 41.10 美元，交易总额为 71,390.70 美元。交易完成后，该董事直接持有公司股票 7,248 股，价值 297,892.80 美元。此销售交易的披露信息可在此处找到。内部人士在过去一个季度内出售了价值 1,539,993 美元的 32,127 股公司股票。公司内部人士持有公司股票的比例为 5.80%。</p>
<h2>关于 Ultragenyx 制药公司（免费报告）</h2>
<p>Ultragenyx 制药公司是一家生物制药公司，专注于在北美、拉丁美洲、日本、欧洲和国际市场识别、收购、开发和商业化用于治疗罕见和超罕见遗传疾病的新产品。其生物制品包括 Crysvita（布罗舒单抗），用于治疗 X 连锁低磷血症和肿瘤诱导性骨软化症；Mepsevii，一种酶替代疗法，用于治疗黏多糖病 VII 的儿童和成人；Dojolvi，用于治疗长链脂肪酸氧化障碍；以及 Evkeeza（依那库单抗），用于治疗纯合子家族性高胆固醇血症。</p>
<h2>精选文章</h2>
<ul>
<li>我们比 Ultragenyx 制药公司更喜欢的五支股票</li>
<li>股市板块：它们是什么，有多少种？</li>
<li>太阳能股票之战：大全或晶科能源，哪个是你的下一个大赢家？</li>
<li>如何计算期权利润</li>
<li>这些中国股票值得买吗？迈克尔·伯里的首选股票说是</li>
<li>高股息房地产投资信托：它们是多样化的理想方式吗？</li>
<li>五低股价股票面临挑战，尽管营收增长强劲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ"/></p>
<p><em>这则即时新闻警报是由叙事科学技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 两个月内将 25,000 美元变成 109,616 美元？（来自 WealthPress）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQx"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Ultragenyx 制药公司股票？</h2>
<p>在考虑购买 Ultragenyx 制药公司股票之前，您需要听到这个。</p>
<p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Ultragenyx 制药公司不在名单上。</p>
<p>尽管 Ultragenyx 制药公司目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

Ultragenyx制药

<p>Peregrine Capital Management LLC 在第二季度增加了对 Ultragenyx Pharmaceutical Inc.的持股比例，现持有 148,813 股，价值约 116,000 美元。其他几家大型投资者也调整了他们的持仓。尽管周五交易下跌，Ultragenyx 报告显示，年度营收增长了 35.7%，季度每股收益为-0.52 美元，超出分析师的预期。该股目前有一个 “中等买入” 的共识评级，平均目标价为 43 美元</p>

<p>Peregrine Capital Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 24.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,813 shares of the biopharmaceutical company's stock after buying an additional 29,474 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.18% of Ultragenyx Pharmaceutical worth $6,116,000 as of its most recent SEC filing.</p>
<ul>
<li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li>
</ul>
<div class="lb-trans"><p>Peregrine Capital Management LLC 根据最新提交给美国证券交易委员会（SEC）的 13F 文件显示，在第二季度增持了 Ultragenyx Pharmaceutical Inc.（纳斯达克股票代码：RARE - Free Report）的股份，持股比例增加了 24.7%。该公司在本季度购入了 29,474 股，持有这家生物制药公司的 148,813 股股份。Peregrine Capital Management LLC 在最新提交的 SEC 文件中拥有的 Ultragenyx Pharmaceutical 股份价值 611.6 万美元，占该公司价值的约 0.18%。</p>
<ul>
<li>分析师表示这两家中型生物科技公司有着两倍的潜力</li>
</ul>
</div><p>Several other large investors have also made changes to their positions in RARE. Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical in the 1st quarter valued at $28,000. UMB Bank n.a. raised its position in Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 352 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Ultragenyx Pharmaceutical by 622.3% during the 1st quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 865 shares in the last quarter. Van ECK Associates Corp grew its stake in Ultragenyx Pharmaceutical by 34.0% during the 4th quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company's stock worth $75,000 after buying an additional 400 shares during the last quarter. Finally, International Assets Investment Management LLC grew its stake in Ultragenyx Pharmaceutical by 3,182.4% during the 4th quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company's stock worth $80,000 after buying an additional 1,623 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些大型投资者也对他们在 RARE 的持仓进行了调整。Headlands Technologies LLC 在第一季度购入了 Ultragenyx Pharmaceutical 的新股份，价值 28,000 美元。UMB Bank n.a.在第二季度增加了对 Ultragenyx Pharmaceutical 的持仓，持股比例增长了 58.1%。UMB Bank n.a.现在拥有 958 股这家生物制药公司的股份，价值 39,000 美元，较上一季度增持了 352 股。GAMMA Investing LLC 在第一季度将其对 Ultragenyx Pharmaceutical 的持仓增加了 622.3%。GAMMA Investing LLC 现在拥有 1,004 股这家生物制药公司的股份，价值 47,000 美元，较上一季度增持了 865 股。Van ECK Associates Corp 在第四季度将其对 Ultragenyx Pharmaceutical 的持仓增加了 34.0%。Van ECK Associates Corp 现在拥有 1,578 股这家生物制药公司的股份，价值 75,000 美元，较上一季度增持了 400 股。最后，International Assets Investment Management LLC 在第四季度将其对 Ultragenyx Pharmaceutical 的持仓增加了 3,182.4%。International Assets Investment Management LLC 现在拥有 1,674 股这家生物制药公司的股份，价值 80,000 美元，较上一季度增持了 1,623 股。该公司的 97.67% 股份由机构投资者和对冲基金持有。</p>
</div><h2>Ultragenyx Pharmaceutical Price Performance</h2>
<div class="lb-trans"><h2>Ultragenyx Pharmaceutical 股价表现</h2>
</div><p>Shares of Ultragenyx Pharmaceutical stock traded down $0.18 on Friday, reaching $56.78. 754,442 shares of the company traded hands, compared to its average volume of 805,332. The company has a 50 day moving average of $47.29 and a 200 day moving average of $45.70. The firm has a market capitalization of $4.72 billion, a PE ratio of -7.07 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.52 and a 52 week high of $58.73.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical 股票周五下跌 0.18 美元，收于 56.78 美元。公司成交 754,442 股，相比平均成交量 805,332 股有所下降。该公司的 50 日移动平均价为 47.29 美元，200 日移动平均价为 45.70 美元。该公司市值为 47.2 亿美元，市盈率为-7.07，β系数为 0.56。Ultragenyx Pharmaceutical Inc.的 52 周最低价为 31.52 美元，52 周最高价为 58.73 美元。</p>
</div><p>Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.64) by $0.12. The business had revenue of $147.03 million for the quarter, compared to analyst estimates of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company's revenue was up 35.7% on a year-over-year basis. During the same quarter last year, the firm earned ($2.25) EPS. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.24 earnings per share for the current year.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical（纳斯达克股票代码：RARE - Get Free Report）最近公布了截至 8 月 1 日星期四的季度财报。该生物制药公司报告本季度每股亏损 1.52 美元，超过了分析师预期的 1.64 美元，增加了 0.12 美元。本季度营收为 1.4703 亿美元，超过分析师预期的 1.232 亿美元。Ultragenyx Pharmaceutical 的净利润率为-121.57%，净资产收益率为-266.02%。公司营收同比增长 35.7%。去年同期，该公司每股亏损 2.25 美元。分析师预计，Ultragenyx Pharmaceutical Inc.今年将实现每股-6.24 美元的盈利。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research analysts recently issued reports on the company. Wedbush raised their price target on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a &#34;neutral&#34; rating in a research note on Friday, August 2nd. Robert W. Baird boosted their target price on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, May 31st. Cantor Fitzgerald boosted their target price on Ultragenyx Pharmaceutical from $115.00 to $116.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, August 2nd. Canaccord Genuity Group reiterated a &#34;buy&#34; rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Finally, Wells Fargo &amp; Company upped their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $87.43.</p>
<div class="lb-trans"><p>一些研究分析师最近发布了关于该公司的报告。Wedbush 将 Ultragenyx Pharmaceutical 的目标股价从 43.00 美元上调至 46.00 美元，并在 8 月 2 日星期五的研究报告中给予该股票 “中性” 评级。Robert W. Baird 将 Ultragenyx Pharmaceutical 的目标股价从 68.00 美元上调至 72.00 美元，并在 5 月 31 日星期五的研究报告中给予该股票 “跑赢市场” 评级。Cantor Fitzgerald 将 Ultragenyx Pharmaceutical 的目标股价从 115.00 美元上调至 116.00 美元，并在 8 月 2 日星期五的研究报告中给予该股票 “增持” 评级。Canaccord Genuity Group 重申了对 Ultragenyx Pharmaceutical 的 “买入” 评级，并设定了 111.00 美元的目标股价。Wells Fargo &amp; Company 将 Ultragenyx Pharmaceutical 的目标股价从 72.00 美元上调至 75.00 美元，并在 8 月 2 日星期五的研究报告中给予该股票 “增持” 评级。两位股票研究分析师给予该股票持有评级，十三位给予买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “中度买入”，平均目标股价为 87.43 美元。</p>
</div><p><strong>Get Our Latest Report on RARE</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 RARE 的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部交易</h2>
</div><p>In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total value of $1,003,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,243,985 shares of the company's stock, valued at $112,580,727.45. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. In other news, CEO Emil D. Kakkis sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total transaction of $1,003,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,243,985 shares of the company's stock, valued at $112,580,727.45. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the business's stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.10, for a total transaction of $71,390.70. Following the transaction, the director now directly owns 7,248 shares of the company's stock, valued at $297,892.80. The disclosure for this sale can be found here. Insiders have sold 32,127 shares of company stock valued at $1,539,993 over the last quarter. Corporate insiders own 5.80% of the company's stock.</p>
<div class="lb-trans"><p>另外，Ultragenyx 制药公司的首席执行官 Emil D. Kakkis 在交易日期为 8 月 6 日星期二出售了 20,000 股 Ultragenyx 制药公司股票。这些股票的平均售价为 50.17 美元，总价值为 1,003,400.00 美元。交易完成后，首席执行官直接持有公司股票 2,243,985 股，价值 112,580,727.45 美元。该销售交易已在提交给证券交易委员会的申报文件中披露，可通过此链接访问。另外，首席执行官 Emil D. Kakkis 还在 8 月 6 日星期二进行的另一笔交易中出售了该公司股票的 20,000 股。这些股票的平均售价为 50.17 美元，交易总额为 1,003,400.00 美元。交易完成后，首席执行官直接持有公司股票 2,243,985 股，价值 112,580,727.45 美元。该交易已在提交给证券交易委员会的申报文件中披露，可通过 SEC 网站访问。此外，董事 Corazon（Corsee）D. Sanders 在 6 月 10 日星期一进行的交易中出售了 1,737 股公司股票。这些股票的平均售价为 41.10 美元，交易总额为 71,390.70 美元。交易完成后，该董事直接持有公司股票 7,248 股，价值 297,892.80 美元。此销售交易的披露信息可在此处找到。内部人士在过去一个季度内出售了价值 1,539,993 美元的 32,127 股公司股票。公司内部人士持有公司股票的比例为 5.80%。</p>
</div><h2>About Ultragenyx Pharmaceutical (Free Report)</h2>
<div class="lb-trans"><h2>关于 Ultragenyx 制药公司（免费报告）</h2>
</div><p>Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.</p>
<div class="lb-trans"><p>Ultragenyx 制药公司是一家生物制药公司，专注于在北美、拉丁美洲、日本、欧洲和国际市场识别、收购、开发和商业化用于治疗罕见和超罕见遗传疾病的新产品。其生物制品包括 Crysvita（布罗舒单抗），用于治疗 X 连锁低磷血症和肿瘤诱导性骨软化症；Mepsevii，一种酶替代疗法，用于治疗黏多糖病 VII 的儿童和成人；Dojolvi，用于治疗长链脂肪酸氧化障碍；以及 Evkeeza（依那库单抗），用于治疗纯合子家族性高胆固醇血症。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Ultragenyx Pharmaceutical</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?</li>
<li>How to Calculate Options Profits</li>
<li>Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Five Below Stock Faces Challenges Despite Strong Revenue Growth</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们比 Ultragenyx 制药公司更喜欢的五支股票</li>
<li>股市板块：它们是什么，有多少种？</li>
<li>太阳能股票之战：大全或晶科能源，哪个是你的下一个大赢家？</li>
<li>如何计算期权利润</li>
<li>这些中国股票值得买吗？迈克尔·伯里的首选股票说是</li>
<li>高股息房地产投资信托：它们是多样化的理想方式吗？</li>
<li>五低股价股票面临挑战，尽管营收增长强劲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RARE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科学技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ $25,000 into $109,616 in two months? (From WealthPress)(Ad)</p>
<div class="lb-trans"><p>→ 两个月内将 25,000 美元变成 109,616 美元？（来自 WealthPress）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9141&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Ultragenyx Pharmaceutical right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Ultragenyx 制药公司股票？</h2>
</div><p>Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Ultragenyx 制药公司股票之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Ultragenyx 制药公司不在名单上。</p>
</div><p>While Ultragenyx Pharmaceutical currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Ultragenyx 制药公司目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

Peregrine Capital Management LLC 收购了 Ultragenyx 制药公司（NASDAQ:RARE）的股份